glp-1 cardiovascular benefit Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action GLP-1 receptor agonists and cardiovascular

More serious but less common risks include pancreatitis and gallbladder disease

We do not know how long someone should stay on the medication, or whether the craving reduction persists after stopping

MK-677 represents a different single-compound approach entirely

10.3390/biomedicines9050468 76 HosokawaS.YoshidaO

Maintaining a structured meal plan helps manage both nutrition and side effects consistently

What is already known on this topic Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a promising drug class that has shown benefits for adults with type 2 diabetes Regulatory authorities have approved several GLP-1RA drugs, and novel drugs are continually emerging, resulting in an urgent need for updated evidence synthesis of the comparative effectiveness of various GLP-1RAs What this study adds Compared with the placebo, all 15 GLP-1RAs had significant effects on glycaemic control, and tirzepatide was the most effective in reducing haemoglobin A 1c and fasting plasma glucose concentrations CagriSema induced the highest weight reduction in adults with type 2 diabetes, followed by tirzepatide and retatrutide Several GLP-1RAs resulted in a significantly higher odds ratio of discontinuation due to adverse events than placebo, raising safety concerns about gastrointestinal adverse events, especially at high doses Ethics statements Ethical approval Not required